Lupin Launches World’s First Fixed-dose Triple Combination Drug, Vilfuro-G® for COPD Management in India
Lupin announced the launch of Vilfuro-G, the world's first fixed-dose triple combination drug (FDC) for the treatment of COPD in India.
Vilfuro-G is available in a single-strength fixed dose, with a recommended once-daily dosage for the treatment of COPD, which refers to a group of diseases that cause airflow blockage and breathing-related problems.
Did you Know
COPD stands for: chronic obstructive pulmonary disease.